
I certify that this document is being deposited on <u>12 March 2001</u>, with the United States Postal Service as first class mail under 37 C.F.R. § 1.8 and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231

13/13 AW 4-15.01





RECEIVED

Owen Bates

MAR 3 0 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

CORMIER, M. et al.

Serial No.:

09/190,887

Filed:

12 November 1998

Title:

Buffered Drug Formulations

for Transdermal Electrotransport

Delivery

Attorney Docket No. ARC2589CIP1

Group Art Unit:

1618

Examiner:

CELSA, B.

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents Washington, DC 20231

Sir:

The Office Action in this Application dated 12 September 2001, has been carefully reviewed. In response, the Applicants have amended the claims and made the following elections and provided the remarks herein.

AMENDMENTS

1. (Amended) A formulation for transdermal electrotransport delivery, comprising an aqueous solution of a drug [or an electrolyte] and a dipeptide buffer, the dipeptide buffer comprising a polypeptide chain of 2 to 5 amino acids and having an isoelectric pH at which the dipeptide